iRadimed Q1 2026 Earnings Call Transcript

Quartr
Provided by Quartr
May 1, 2026

Key Takeaways

  • Positive Sentiment: Record quarter and raised guidance: Q2 revenue was $20.4M (+14% YoY) with 78% gross margin and GAAP diluted EPS of $0.45 (+18% YoY); management raised FY2025 revenue guidance to $80.0–$82.5M, raised EPS ranges, and declared a $0.17 quarterly dividend.
  • Positive Sentiment: FDA clearance of the MRidium 3870: Management calls the clearance a "seminal" event and expects the new pump (≈12% higher ASP) to unlock large replacement demand from >6,200 U.S. 5+-year-old channels, targeting an eventual domestic pump device revenue lift toward ~$50M in 2026.
  • Neutral Sentiment: Backlog and commercial cadence: The company reports a record backlog (pump backlog ~5–6 months, monitor backlog ~4–5 weeks) and plans a controlled rollout—limiting broad selling of the 3870 through year‑end—so pump bookings may be muted initially even while revenue is supported by backlog.
  • Negative Sentiment: Near-term headwinds and international softness: International revenue declined 9% (domestic now ~89% of sales), the facility move will cause short-lived operational inefficiencies, and ongoing capex (final facility payments) could pressure near-term free cash flow and operating expenses.
AI Generated. May Contain Errors.
Earnings Conference Call
iRadimed Q1 2026
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

On listen only mode, and at the end of the call, we will conduct a question and answer session. This call is being recorded today, August 1st, 2025, and contains time-sensitive accurate information only today. Earlier, IRadimed released its financial results for the second quarter of 2025. A copy of this press release announcing the company's earnings is available under the heading News on their website at iradimed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live over the internet on the company's website at iradimed.com, and a replay will be available on the website for the next 90 days. Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Operator

Forward-looking statements focus on future performance, results, plans, and events, and may include the company's expected future results. IRadimed reminds you that future results may differ materially from these forward-looking statements due to several risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section of the company's most recent reports filed with the Securities and Exchange Commission, which may be obtained free from the SEC's website at sec.gov. I would now like to turn the call over to Roger Susi, President and Chief Executive Officer of IRadimed Corporation. Mr. Susi.

Roger Susi
President and CEO at IRadimed Corporation

Thank you, operator. Good morning, and thank you all for joining us on today's call. I am indeed very pleased to report yet another record quarter, marking our 16th consecutive quarter of record revenues. For the second quarter of 2025, we achieved revenue of $20.4 million, a 14% increase over the same period last year. Gross profit came in at 78%, with earnings very strong as well. GAAP diluted earnings per share increasing 18% from Q2 of 2024. Pump shipments led performance in the quarter as our MRidium 3860+ continued to excel in Q2.

Roger Susi
President and CEO at IRadimed Corporation

In addition to the great pump performance, I am also very happy to report that shipments of our MR patient monitor grew 9% and that bookings in Q2 indicate that our emphasis on monitoring sales for 2025 can be expected to achieve our plans with this product line as well. I'd like to quickly follow up on comments regarding tariffs and DOGE impacts, which we had discussed at some length during our earnings call of Q1. We can now look back and see that though tariffs had been collected on some of the components we utilize, the actual impact is still very small. We do feel, however, that as tariffs become stable and finalized, especially Chinese tariffs, and as pre-tariff inventories dwindle here within our stocks, we will have a better idea of the measurable tariff impacts to manage and report upon in the future.

Roger Susi
President and CEO at IRadimed Corporation

As for DOGE effects upon various agencies and possible issues secondarily affecting IRadimed, such impacts did not materialize. As announced on May 22nd, the FDA cleared our new 3870 IV pump systems for distribution. With this long-awaited and hard-fought FDA action, the road ahead for IRadimed is clear and wide. Since the founding of IRadimed 20 years ago, this clearance and the sales growth that the new pump will ignite will prove to be a seminal event. Reflecting a moment, when I founded IRadimed, frankly, though we had a strong vision that an MRIV pump would be a highly successful niche device, my revenue targets from then now appear overly modest, being in the double digits. That revenue vision looks to be passing the $100 million revenue run rate as we progress through 2026.

Roger Susi
President and CEO at IRadimed Corporation

I could not be prouder of what we have done with this fascinating MRI niche. Let me share how we envision these next several quarters. Most of you have seen the effect on the sales of our existing legacy pump, the original design core from 20 years ago, when we simply discontinued offering service contracts for units 7 years and older. This action led a number of customers to replace older 3860 pumps with newer, newly manufactured 3860 pumps. Now that we have a new state-of-the-art pump with 20 years of technological advancement, we anticipate a huge demand for replacing older 3860 model pumps, starting at the five-year-old level. For context, in the U.S. market alone, there are over 6,200 five-plus-year-old 3860, 61 pump channels up for replacement. We currently sell approximately 1,000 such channels annually into the domestic market.

Roger Susi
President and CEO at IRadimed Corporation

We will target adding to that base of 1,000 channels per year, another 1,000 channels through update replacement sales from that 6,200 units that are over five years old. This will be our target in 2026. In subsequent years, we expect to increase the drawdown of old pump channels from 1,000 to over 2,000 and growing, and so on. Adding the increased sales for replacements into the current base run rate of 1,000 a year, you can understand why I see piercing that $100 million revenue run rate in 2026 and continuing strong growth for years afterwards.

Roger Susi
President and CEO at IRadimed Corporation

To put numbers on this, for our domestic opportunity only, as we sell 2,000 3870 pump channels annually with a slightly higher ASP, we anticipate, the 2025 domestic pump device revenue currently expected at $28 million in 2025 will become nearly $50 million. Adding in Disposables, then international sales, plus the MR monitor business, one can understand my confidence in breaking through this $100 million revenue rank. Now let's discuss our updated financial guidance. For the third quarter of 2025, we expect revenue of $20.5 million-$20.9 million, representing 12%-14% growth over Q3 2024, which was $18.3 million.

Roger Susi
President and CEO at IRadimed Corporation

We anticipate a GAAP diluted earnings per share of $0.41-$0.45 and non-GAAP diluted earnings per share of $0.45-$0.49, reflecting a 10%-12% growth over Q3 2024's $0.40-$0.43, respectively. Tempered by anticipated but short-lived operational inefficiencies during our facility transition, which we've just moved into our new building. For the full year 2025, we are raising our guidance to reflect our strong first half performance. We now expect revenues of $80 million-$82.5 million, up from our prior range of $78 million-$82 million, representing 9%-13% growth over 2024's $73.2 million revenues.

Roger Susi
President and CEO at IRadimed Corporation

GAAP diluted earnings per share now expected to be $1.60-$1.70, up from $1.55-$1.65, and non-GAAP diluted earnings per share is $1.76-$1.86, up from $1.71-$1.81. These ranges account for approximately $2.6 million in stock-related compensation expense, net of tax for the full year, and $0.6 million for Q3. We also remain committed to delivering value through our $0.17 per share quarterly dividend declared for Q3 and payable on August 28, 2025. I'll turn the call over to Jack Glenn, our CFO, to review the quarter's financial results in detail.

Jack Glenn
Jack Glenn
CFO at IRadimed Corporation

Thank you, Roger, and good morning, everyone. As in the past, our results are reported on a GAAP basis and a non-GAAP basis. You can find a description of our non-GAAP operating measures in this morning's earnings release and a reconciliation of these non-GAAP measures to the GAAP measure on the last page of today's release. For the three months ended June 30, 2025, we reported revenue of $20.4 million, a 14% increase from $17.9 million in the second quarter of 2024. This growth was driven by strong performance across all product lines, with MRI-compatible IV infusion pump systems contributing $8.2 million, up 19% year-over-year, and patient vital signs monitoring systems contributing $5.9 million, up 9%.

Jack Glenn
Jack Glenn
CFO at IRadimed Corporation

Disposables revenue grew 14% to $4.2 million, reflecting increased utilization of our devices, while ferromagnetic detection systems and services revenue also saw a solid gain. Domestic sales increased 18% to $18.2 million, and international sales decreased 9% to $2.2 million. Overall, domestic revenue accounted for 89% of total revenue for Q2 2025, compared to 86% for Q2 2024. Gross profit was $16 million, up 14% from $14 million in Q2 2024, with a gross margin of 78% consistent with the prior year. The strong margin performance was supported by increased overhead absorption as we built inventory ahead of the new facility's opening.

Jack Glenn
Jack Glenn
CFO at IRadimed Corporation

Operating expenses for the quarter were $9.2 million, up 9% from $8.4 million in Q2 2024, driven by higher sales and marketing expenses to support our growth and modest increases in general administrative costs. Research and development expenses remained steady at approximately $0.9 million. Income from operations grew 21% to $6.8 million from $5.6 million in Q2 2024. Tax expense for the quarter was $1.6 million, resulting in an effective tax rate of 21.2%. Net income was $5.8 million or $0.45 per diluted share, an 18% increase from $4.9 million or $0.38 per diluted share in Q2 2024.

Jack Glenn
Jack Glenn
CFO at IRadimed Corporation

On a non-GAAP basis, net income was $6.4 million or $0.49 per diluted share, up 17% from $0.42, excluding $0.6 million of stock-based compensation expense net of tax. Turning to our balance sheet. We ended the quarter with cash and cash equivalents of $53 million, up from $52.2 million at year-end 2024. Cash flow from operations was a strong $7.7 million for the quarter, up 17% from $6.6 million in Q2 of 2024, and $12 million for the first half, up 14% from $10.5 million. Free cash flow was $4.9 million for the quarter and $5.3 million for the first half, reflecting capital expenditures of $6.7 million year to date, primarily related to the new facility.

Jack Glenn
Jack Glenn
CFO at IRadimed Corporation

We expect final payments of approximately $1.1 million for the facility in Q3, bringing the total construction cost to approximately $12.6 million. With that, I will turn the call over to the operator for questions. Operator?

Operator

Thank you. We will now begin the question and answer session. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Frank Takkinen from Lake Street Capital Markets.

Frank Takkinen
Analyst at Lake Street Capital Markets

Great. Thank you for taking the questions. Congrats on all the progress and congrats on the MRidium 3870 clearance. I was hoping to start with one on kinda current backlog. I saw the comment and heard your positive remarks about a record backlog. Can you talk about the composition of that backlog and then kind of marry that into how you expect MRidium 3860+ sales to trend in front of MRidium 3870 launching?

Jack Glenn
Jack Glenn
CFO at IRadimed Corporation

Sure. I can take that one, Frank. Yeah, as we said, it was a record backlog as of June 30, and it was composed of both, you know, certainly as we've discussed the pumps, but also very strong monitoring backlog as well. That certainly gives us, I think, good visibility into the second half of the year, especially with, you know, before we commercialize and introduce the MRidium 3870, that we have a strong backlog of MRidium 3860+ to get us through what we see to, you know, the second half of the year.

Frank Takkinen
Analyst at Lake Street Capital Markets

Got it. Okay. That's helpful.

Roger Susi
President and CEO at IRadimed Corporation

Frank, good to hear your voice. Thanks for the question. Maybe that was a two-parter. You also want to know how the, maybe the 3860s, the old pump, the legacy pump orders would trend. I mean, they're still trending extraordinarily strong, and that's why we're so bullish as the year wraps up. We really feel at this point that we're more or less in control of how that'll trail off. That comes to the timing of when we actually unleash our sales team to go out and actively in mass, you know, start discussing this new pump. They're not doing that at this point. We don't want them to do that. Certainly somewhere in December is where we'll do that.

Roger Susi
President and CEO at IRadimed Corporation

We think the orders will still, for the older pump, will still be rather significant, quite strong, right up until we do start to talk about the MRidium 3870 somewhere in December.

Frank Takkinen
Analyst at Lake Street Capital Markets

Got it. Very helpful, [clear]. Roger, I wanted to follow up on some of your comments. I appreciate all the color on kind of MRidium 3870 renewal potential. How do you think about the cadence of that ramp to the $50 million of pump revenue? I assume it builds over time, but any thoughts around how that kind of scales throughout 2026 would be helpful.

Roger Susi
President and CEO at IRadimed Corporation

Well, it'll Our plan, as we mentioned before, I think we went over this on previous calls, is in Q4, we'll sell a few 3870s. It'll be insignificant to revenue, the purpose is not so much to generate revenue. It's to generate a few of, it's basically to generate feedback from a few of our stronger users as to, you know, any user suggestions or little tweaks that we might want to, last-minute tweaks, put into the product. We plan to start that, right around Christmas time, New Year's. Of course, then we'll also be fully out showing the MRidium 3870 by that point as well.

Roger Susi
President and CEO at IRadimed Corporation

You know, the bookings of the new pump, in the first quarter, you know, they won't be all the way ramped up to these numbers I was talking about at that point, certainly. They'll be just starting to bring in revenue. As you understand, I think everybody understands this, there's a pipeline and an inertia to people writing POs. Even though due to the, this resale of 3860s that we've had going on, there will be a number of customers who have the funds budgeted, and we'll be switching those to the new pump as we can. Q1 on pump bookings overall, I expect to be weak. We'll fill it with. The revenue won't be though, because we have such a huge backlog.

Roger Susi
President and CEO at IRadimed Corporation

You won't really see it by looking at revenue. Bookings we anticipate in Q1 for pumps should be a little bit weak. By 2nd quarter, we should be back to pretty strong run rate on booking pumps, which will just accelerate through Q3 and Q4. Certainly by the end of 2026, as I think you could glean from what I was saying earlier, the overall run rate of the business will be, you know, towards that $100 million number and past it.

Frank Takkinen
Analyst at Lake Street Capital Markets

Got it. That makes sense. Just last one for me. Obviously, you have a very large opportunity to harvest the renewal cycle with the MRidium 3870. Curious if you think the functionality and improvements of the MRidium 3870 could expand the overall market and demand in the, in the pump area.

Roger Susi
President and CEO at IRadimed Corporation

You know, I haven't really even factored that in. As you've heard us say over the last few years, you know, you've been on these calls for a while, and those that have been on these calls for a while have heard us say. You know, it's two decades improved over what we've been selling. We think and we designed it to address one of the Achilles heels of this old pump, which was its usability. We made the new pump, as we've talked about in the past, you know, it has a very, compared to the old pump, let's call it much more modern, interactive user interface.

Roger Susi
President and CEO at IRadimed Corporation

We have little graphics and animations on it that help lead the user through the use of the pump. To some extent, we think that is the single largest deterrent that slows down the adoption of the older pump. Yes, we feel that with the new pump being much more modern and with this, much more user-friendly help that comes on the screen to guide the users through its use, that the greenfield, those folks that have sat on the fence and not adopted the older pump, we should knock them off at an accelerating rate. I didn't factor that into these numbers I'm talking about. That is upside.

Frank Takkinen
Analyst at Lake Street Capital Markets

Got it. Very helpful. Congrats on all the progress. Thanks for taking the questions.

Roger Susi
President and CEO at IRadimed Corporation

Thanks for having me, Takkinen.

Operator

Thank you. One moment for our next question. Our next question comes from the line of Jason Wittes from ROTH.

Jason Wittes
Managing Director and Analyst at ROTH

Hi, thanks for taking the question. Solid quarter here. First off, on the new pump, is there an ASP increase that we should be factoring in here?

Roger Susi
President and CEO at IRadimed Corporation

I missed that. What was-.

Jason Wittes
Managing Director and Analyst at ROTH

ASP pricing on the new pump.

Roger Susi
President and CEO at IRadimed Corporation

Oh, yeah. I kind of alluded to that in what I said. We anticipate the ASP will be, you know, a little bit higher. We've had this question a few times in previous calls.

Jason Wittes
Managing Director and Analyst at ROTH

Mm-hmm.

Roger Susi
President and CEO at IRadimed Corporation

Now we're finally, you know, in these last, just these last few weeks since we got clearance from FDA, you know, we've really put the pencil to the pricing and modeled the pricing. It looks like it's coming out, where it's probably gonna be around 12-ish%, you know, more than the ASP of the existing pump.

Jason Wittes
Managing Director and Analyst at ROTH

Okay, that's good to hear. I guess I mean, is that possible to put some upward pressure on the gross margins is from that pricing? Can we assume that as well, or is it too early to make that call?

Roger Susi
President and CEO at IRadimed Corporation

Well, it's. Yeah, it should be reflected in that. It might actually be reflected a little bit more so even in the gross margin because, you know,

Jason Wittes
Managing Director and Analyst at ROTH

I meant gross margins, yes. Operating margins are even more important, that's even better to hear. Thank you. On the backlog, how long is it taking you guys to fulfill your backlog at this point? What is the timing from an order that goes in backlog to getting fulfilled?

Roger Susi
President and CEO at IRadimed Corporation

It's a little different between the pump and the monitors. The monitor backlog's running, as I recall, about four weeks, five weeks, somewhere in there. A pump backlog is running about five months, five to six months. We're letting that take place. As I mentioned, we anticipate bookings for pumps will be low in Q1 as we transition, but revenue won't be because we've got this huge backlog of these older pumps to deliver. Yeah, it's a, there's a good length of time in the backlog.

Jason Wittes
Managing Director and Analyst at ROTH

Okay, that's helpful. It sounds like customers, there are going to be some upgrades from the backlog, but it doesn't sound like per se, customers expecting pumps in the next, certainly for the rest of this year are initially going to be motivated to upgrade. They'll be happy getting just a new pump. Is that the right way to think about it, or do you anticipate there's some upgrades there as well?

Roger Susi
President and CEO at IRadimed Corporation

In this year, no. We're only targeting a limited number of facilities, basically three, that we're gonna deliver 40 to 50 of the new pumps into to watch.

Jason Wittes
Managing Director and Analyst at ROTH

Oh, I see.

Roger Susi
President and CEO at IRadimed Corporation

Those customers I mentioned before that we wanna just use more as a just any things that we need to put a finishing touch to that may come up during, you know, watching how people actually interact with and use the pump. That's why we're gonna deliberately have this delay into Q1, is because we're gonna wait for that two, three months of education from what we can learn from initially planting about 40 pumps.

Jason Wittes
Managing Director and Analyst at ROTH

Okay, great. I guess I'll jump back in queue, but thanks for answering the questions.

Roger Susi
President and CEO at IRadimed Corporation

Thanks. We can talk soon, Jason.

Operator

Thank you. At this time, I would now like to turn the conference back over to Roger Susi for closing remarks.

Roger Susi
President and CEO at IRadimed Corporation

Again, thank you, operator. I'd like to thank those who have ridden along with us on this MR niche journey, which though always maintaining great revenue growth and margins, at times provided a few white-knuckle twists and turns, mainly due to the clearance process for this new pump. It is with very clear vision, we now see that road ahead providing us many more years of rewarding growth as we can, after nearly 20 years, offer our customers a path to move their MRIV solution delivery onto our new exciting pump platform. Thank you.

Operator

Thank you. This concludes the call. You may now disconnect.

Analysts
    • Frank Takkinen
      Analyst at Lake Street Capital Markets
    • Jack Glenn
      CFO at IRadimed Corporation
    • Jason Wittes
      Managing Director and Analyst at ROTH
    • Roger Susi
      President and CEO at IRadimed Corporation
Powered by Quartr